Thomas Saur

Overview

Sanofi global CMC lead for microbial biologics and genomic medicine with 29 years in biologics development, advocate for process simplification, continuous downstream processing, and patient affordability as a core obligation Thomas Saur has spent 29 years at Sanofi (formerly Bayer), starting in vaccines development in 1997; he currently leads global CMC for microbial biologics and recently added responsibility for a genomic medicine unit. Patient affordability and cost pressure are critical failures of the current bioprocessing model: some approved drugs are not commercialized in certain markets solely due to pricing, which Saur views as an unacceptable outcome of the industry's cost structure. (Segment 2 (05:00-10:00))